Myriad Genetics to Release Second Quarter Financial Results on August 3, 2021
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced its quarterly earnings conference call for the second quarter ended June 30, 2021. The call is scheduled for August 3, 2021, at 4:30 p.m. EDT, with earnings released prior to market opening on the same day. Key executives, Paul J. Diaz and R. Bryan Riggsbee, will discuss the company's performance. Interested parties can join via dial-in or webcast. Myriad Genetics specializes in genetic testing and precision medicine, aimed at improving patient care and reducing healthcare costs.
- None.
- None.
SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended June 30, 2021, at 4:30 p.m. EDT on Tuesday, August 3, 2021. The company’s quarterly earnings will be released prior to the market opening on August 3, 2021. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad Genetics’ performance for the second quarter of 2021.
The dial-in number for domestic callers is 1-800-920-2191. International callers may dial +1-212-271-4651. All callers will be asked to reference reservation number 21996351. An archived replay of the call will be available for seven days by dialing 1-800-633-8284 and entering the reservation number above. The conference call along with a slide presentation will be available through a live webcast at www.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, EndoPredict, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.
| Media Contact: | Investor Contact: |
| Jared Maxwell | Nathan Smith |
| (801) 505-5027 | (801) 505-5067 |
| jmaxwell@myriad.com | Nathan.Smith@myriad.com |
FAQ
When is Myriad Genetics' earnings conference call for Q2 2021?
What will be discussed during Myriad Genetics' earnings call?
How can I access the Myriad Genetics earnings call?
What is the stock symbol for Myriad Genetics?
